These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 19357504

  • 1. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
    Thøgersen AM, Nilsson TK, Weinehall L, Boman K, Eliasson M, Hallmans G, Jansson JH.
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):340-6. PubMed ID: 19357504
    [Abstract] [Full Text] [Related]

  • 2. Elevated plasma homocysteine: cause or consequence of myocardial infarction?
    Hultdin J, Thøgersen AM, Jansson JH, Nilsson TK, Weinehall L, Hallmans G.
    J Intern Med; 2004 Dec; 256(6):491-8. PubMed ID: 15554950
    [Abstract] [Full Text] [Related]

  • 3. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction.
    Andreotti F, Hackett DR, Haider AW, Roncaglioni MC, Davies GJ, Beacham JL, Kluft C, Maseri A.
    Thromb Haemost; 1992 Dec 07; 68(6):678-82. PubMed ID: 1287882
    [Abstract] [Full Text] [Related]

  • 4. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
    Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC.
    N Engl J Med; 1995 Mar 09; 332(10):635-41. PubMed ID: 7845427
    [Abstract] [Full Text] [Related]

  • 5. Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction.
    Lundblad D, Dinesen B, Rautio A, Røder ME, Eliasson M.
    J Intern Med; 2005 Jul 09; 258(1):13-20. PubMed ID: 15953128
    [Abstract] [Full Text] [Related]

  • 6. Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized-controlled trial.
    Claesson M, Birgander LS, Jansson JH, Lindahl B, Burell G, Asplund K, Mattsson C.
    J Intern Med; 2006 Oct 09; 260(4):320-31. PubMed ID: 16961669
    [Abstract] [Full Text] [Related]

  • 7. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction.
    Van Dreden P, Rousseau A, Savoure A, Lenormand B, Fontaine S, Vasse M.
    Blood Coagul Fibrinolysis; 2009 Dec 09; 20(8):635-41. PubMed ID: 19809306
    [Abstract] [Full Text] [Related]

  • 8. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8-11 years.
    Nilsson TK, Boman K, Jansson JH, Thøgersen AM, Berggren M, Broberg A, Granlund A.
    Thromb Res; 2005 Dec 09; 116(3):249-54. PubMed ID: 15935834
    [Abstract] [Full Text] [Related]

  • 9. Increased risk and worse prognosis of myocardial infarction in patients with prior hospitalization for epilepsy--the Stockholm Heart Epidemiology Program.
    Janszky I, Hallqvist J, Tomson T, Ahlbom A, Mukamal KJ, Ahnve S.
    Brain; 2009 Oct 09; 132(Pt 10):2798-804. PubMed ID: 19717532
    [Abstract] [Full Text] [Related]

  • 10. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
    Boman KO, Jansson JH, Nyhlén KA, Nilsson TK.
    Thromb Haemost; 2002 Feb 09; 87(2):311-6. PubMed ID: 11859853
    [Abstract] [Full Text] [Related]

  • 11. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
    Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, Maruyama I, Tei C.
    Thromb Haemost; 2001 Nov 09; 86(5):1197-203. PubMed ID: 11816707
    [Abstract] [Full Text] [Related]

  • 12. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
    Speidl WS, Zeiner A, Nikfardjam M, Geppert A, Jordanova N, Niessner A, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K.
    J Am Coll Cardiol; 2005 Jan 04; 45(1):30-4. PubMed ID: 15629369
    [Abstract] [Full Text] [Related]

  • 13. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project.
    Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B.
    Thromb Res; 2005 Jan 04; 116(3):223-32. PubMed ID: 15935831
    [Abstract] [Full Text] [Related]

  • 14. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U.
    Arterioscler Thromb Vasc Biol; 2000 Aug 04; 20(8):2019-23. PubMed ID: 10938026
    [Abstract] [Full Text] [Related]

  • 15. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?
    Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, Fortmann SP, Quertermous T, Hlatky MA, Atherosclerotic Disease, Vascular Function and Genetic Epidemiology Advance (ADVANCE) Study.
    Am Heart J; 2007 Dec 04; 154(6):1059-64. PubMed ID: 18035075
    [Abstract] [Full Text] [Related]

  • 16. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
    Pradhan AD, LaCroix AZ, Langer RD, Trevisan M, Lewis CE, Hsia JA, Oberman A, Kotchen JM, Ridker PM.
    Circulation; 2004 Jul 20; 110(3):292-300. PubMed ID: 15238458
    [Abstract] [Full Text] [Related]

  • 17. C-reactive protein, prothrombotic imbalance and endothelial dysfunction in acute coronary syndromes without ST elevation.
    Apetrei E, Ciobanu-Jurcuţ R, Rugină M, Gavrilă A, Uscătescu V.
    Rom J Intern Med; 2004 Jul 20; 42(1):95-102. PubMed ID: 15529598
    [Abstract] [Full Text] [Related]

  • 18. Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction.
    Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjärnlund A, Jern C, Boman K.
    Thromb Haemost; 2002 Jan 20; 87(1):105-9. PubMed ID: 11848437
    [Abstract] [Full Text] [Related]

  • 19. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
    Schved JF, Gris JC, Arnaud A, Martinez P, Sanchez N, Wautier JL, Sarlat C.
    J Lab Clin Med; 1992 Sep 20; 120(3):411-9. PubMed ID: 1517688
    [Abstract] [Full Text] [Related]

  • 20. Endothelial marker proteins in hyperhomocysteinemia.
    de Jong SC, Stehouwer CD, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ.
    Thromb Haemost; 1997 Nov 20; 78(5):1332-7. PubMed ID: 9408014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.